Last reviewed · How we verify
SOR007 Ointment 1.0%
At a glance
| Generic name | SOR007 Ointment 1.0% |
|---|---|
| Sponsor | DFB Soria, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Topical SOR007 Ointment for Cutaneous Metastases (PHASE1, PHASE2)
- Study of SOR007 Ointment for Actinic Keratosis (PHASE2)
- Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test (PHASE1)
- Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SOR007 Ointment 1.0% CI brief — competitive landscape report
- SOR007 Ointment 1.0% updates RSS · CI watch RSS
- DFB Soria, LLC portfolio CI